Affimed's fully human anti-thrombosis antibody shows in vivo efficacy with reduced side effects
The preclinical studies, conducted at the Dept. Cardiology and Dept. Clinical Pharmacology of Freiburg University, Germany and at the Baker Heart Research Institute in Melbourne, Australia demonstrated that the antithrombotic effect is comparable to the clinically used conformation-unspecific GPIIb/GPIIIa blockers tirofiban and eptifibatide. However, in clear contrast to these blockers, Affimed's antibody did not prolong bleeding times. This antibody thus represents a novel future approach for antiplatelet therapy.
Original publication: Schwarz M, Meade G, Stoll P, Ylanne J, Bassler N, Chen YC, et al.; "Conformation-specific blockade of the integrin GPIIb/IIIa: A novel antiplatelet strategy that selectively targets activated platelets"; Circ Res. 2006; 99:25-33.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.